Nuveen LLC Acquires Shares of 71,631 Amedisys, Inc. $AMED

Nuveen LLC acquired a new stake in Amedisys, Inc. (NASDAQ:AMED) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 71,631 shares of the health services provider’s stock, valued at approximately $6,635,000. Nuveen LLC owned 0.22% of Amedisys at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Cerity Partners LLC purchased a new position in shares of Amedisys in the first quarter valued at about $463,000. Fifth Third Bancorp increased its position in shares of Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock valued at $32,000 after acquiring an additional 141 shares during the period. Teacher Retirement System of Texas purchased a new position in shares of Amedisys in the first quarter valued at about $817,000. M&T Bank Corp purchased a new position in shares of Amedisys in the first quarter valued at about $315,000. Finally, CWM LLC increased its position in shares of Amedisys by 16.1% in the first quarter. CWM LLC now owns 2,470 shares of the health services provider’s stock valued at $229,000 after acquiring an additional 343 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of NASDAQ AMED opened at $101.01 on Monday. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $101.02. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.36 and a quick ratio of 1.36. The company’s 50-day moving average is $98.47 and its 200 day moving average is $95.06. The stock has a market capitalization of $3.32 billion, a P/E ratio of 39.30, a P/E/G ratio of 1.34 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.15. Amedisys had a net margin of 3.56% and a return on equity of 12.91%. The company had revenue of $621.86 million for the quarter, compared to analysts’ expectations of $614.61 million. During the same quarter in the previous year, the company earned $0.98 earnings per share. Amedisys’s quarterly revenue was up 5.2% on a year-over-year basis. On average, sell-side analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.50.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.